LiteMab© Sense
Tumor-selective antibodies

pH‑dependent conditionally active therapeutic antibodies

Innovative therapeutic antibodies with unique pH-sensitive properties are emerging as a promising approach in oncology, offering enhanced specificity and reduced on-target off-tumor effects.

These antibodies are designed to be active only in the acidic tumor microenvironment (TME) for improved efficacy and safety profiles.

Are you considering tumor-selective antibodies to increase the therapeutic window while avoiding toxicity? Why selectivity matters?

Tumor-selective antibodies can solve these problems by restricting activity to the tumor site, which can preserve efficacy while lowering systemic toxicity.
Many cancer targets are not truly unique to tumor cells, tumor-selective antibodies can reduce on-target / off-tumor toxicity in healthy tissues
In the context of shedded membrane receptors within the tumor microenvironment, tumor-selective antibodies reduce the risk of sink effects for antigens that are also present in the bloodstream.

Looking to enhance antibody recycling efficiency?

Tumor-selective antibodies enhance the efficiency of recycling strategies by limiting binding to circulating antigens and focusing activity within the tumor microenvironment.
This reduces target-mediated clearance and preserves FcRn-driven recycling, ultimately improving exposure, half-life, and therapeutic index.

Working on complex biologics such as ADCs and multispecifics?

Unlock greater specificity, improved PK and reduced off-target effects with tumor-selective binders

Advantages and applications of pH-sensitive technology

pH-sensitive antibodies offer several significant advantages in therapeutic applications such as improvement of targeting and specificity, increased therapeutic efficacy and optimized pharmacokinetics properties:

Tumor selectivity and improved therapeutic index: exploits differences in pH between tumor (low-pH tumor microenvironment TME) and normal tissues
Reduced Off-tumor effects, minimizing binding to healthy tissues at physiological pH

These innovative antibodies represent a significant advancement in cancer therapeutics, offering the potential for more precise and effective treatments across multiple oncology indications.

How can we support your next-generation candidates?

LiteMab Sense – conditionally active pH-dependent antibody discovery

Backed by Mabqi proprietary know-how on antibody library design, our innovation team developed a next-generation fully human synthetic pH-sensitive naive library based on optimized paratopes.

This approach allows for:

Preferential binding to cancer antigens under acidic tumor microenvironment (TME) conditions
Reduced binding to normal tissues at physiological pH
Potential for improved safety profiles and reduced toxicity

Versatility in therapeutic antibody formats

The pH-sensitive antibody technology demonstrates remarkable adaptability to various pharmaceutical development formats:

Monoclonal Antibodies, Bispecifics and Multispecifics:
Antibody binders with pH-sensitive binding properties are developed to enhance a therapeutic efficacy and reduce side effects. This particular characteristic can be leveraged to precisely target cells in acidic microenvironments, such as tumors.

Antibody-Drug Conjugates (ADCs):
pH-sensitive antibodies can be incorporated into ADCs, potentially enhancing tumor-specific drug delivery and minimizing systemic toxicity.

From target to validated lead, we combine robust selection, in‑depth characterization, and functional validation into a single, efficient process tailored for complex biologics development.

At Mabqi, we have built specialized expertise with innovative technologies and streamlined workflows to efficiently generate developable, functional, conditionally active pH-sensitive antibodies

LiteMab Sense platform designed to support the discovery of tumor-selective antibodies.
- Dedicated pH-sensitive Fully human naive synthetic antibody library : this unique library enables the discovery of antibodies that preferentially bind at low pH and not at physiological pH

- AI-powered dual display platform for high diversity pH-sensitive binders
- Functionality-driven discovery workflow
- Full characterization & functional validation of the binders in 4 months

LiteMab Neo Sense platform empowers pH-sensitive maturation programs
- Program based on your parental clones (discovery, preclinical, clinical stages or on the market)
- Design of a customized pH-sensitive library based on the parental sequence
- AI-powered dual display platform to explore antibody diversity and high affinity pH-sensitive clones
- Functionality-driven discovery workflow
- Full characterization & functional validation of the binders in 6 months

Discovery of pH-sensitive antibodies –

Case study to generate conditionally active pH-sensitive to optimize therapeutic index

Boost your pipeline with next-gen drug candidates!

Curious to explore your challenges with a specialized discovery partner? Let’s connect!

LiteMab© Sense Tumor-selective antibodies